FreeportMcMoRan FCX Leads Mining Stocks Amid Peace Hopes Market Watches Key Levels
Markets Reprice Fed Rate Path Hot Inflation Data Raises Possibility of Rate Hike Before 2027
Oil Prices Slide Over 5 on Iran Talks Optimism Then Recover Some Ground
Michael Price Highlights Contrarian Value Investing Amid Market Volatility
First Trust ETFs Attract 406 Million in Inflows ETF League Tables Show
Three Signs from APEC Reveal Persistent USChina Trade Divide
NNN Q1 2026 Earnings Modest EPS Miss as REIT Maintains Disciplined Capital Allocation
LASR Q1 2026 Earnings EPS Surges Past Expectations by Over 126
Ingevity Corporation Q1 2026 Earnings EPS Surges 45 Above Consensus Stock Rises
EXAS Q4 2025 Earnings Significant EPS Miss Raises Questions on Path to Profitability
GLDG Q1 2026 Earnings NarrowerThanExpected Loss Reflects Cost Discipline in PreRevenue Stage
HOWL Q1 2026 Earnings Narrowed Loss Exceeds Estimates Stock Rises
OCCIN Unchanged at 2475 Preferred Stock Consolidates Between Key Levels
Lumentum Holdings LITE Holds Near 902 as Support and Resistance Levels Come into Focus
Tanger Inc SKT Edges Lower Testing Key Support Levels Amid Cautious Trading
DIAX Edges Lower as Options Overwrite Fund Navigates Support and Resistance
Tactile Systems Technology TCMD Shows Modest Gains Amidst Narrow Trading Range
ADP Private Payrolls Rise 109000 in April Exceeding Expectations Amid Stable Labor Market
DORM Q1 2026 Earnings EPS Miss Weighs on Investor Sentiment
First Merchants Corporation Depository Shares FRMEP Holds Steady at 2505 Key Levels in Focus
Saratoga Investment Corp 8125 Notes due 2027 SAY Hold Steady at 2525 Amid Flat Trading
TPG RE Finance Trust TRTX Holds Steady Near Support as Commercial Real Estate Sentiment Shifts
Brookfield Renewable Partners Edges Higher as Renewable Sector Shows Resilience
Central Garden Pet CENTA Holds Near Support as Consolidation Continues
Blackstone Secured Lending Fund BXSL Holds Near Resistance After Positive Session
Pelican Acquisition Corporation PELI Plunges 1179 Key Support Levels Under Scrutiny
Sagimet Biosciences SGMT Edges Higher as Clinical Momentum Builds